Shares of clinical-stage biotechnology firm Psyence Biomedical Ltd. experienced a significant rally, closing 29.5% higher at $7.60 on April 17, 2026. The surge followed an executive order signed by President Donald Trump the following day, which is designed to accelerate federal research into psychedelic compounds for treating mental health conditions and addiction.
Executive Order Details and Market Impact
The order, issued on April 18, 2026, outlines several key initiatives. It directs the Food and Drug Administration (FDA) to expedite the review process for certain psychedelic-based drug applications. Furthermore, it establishes a pathway invoking "Right to Try" provisions, allowing eligible patients to access investigational therapies. The policy also allocates $50 million in federal funding to support state-level research efforts into these substances.
For Psyence Biomedical, a company that supplies Good Manufacturing Practice (GMP)-grade ibogaine, the announcement represents a potential catalyst. Ibogaine, a naturally occurring psychoactive substance, is being studied for its potential in treating addiction and post-traumatic stress disorder (PTSD). The company has emphasized its readiness to provide ethically sourced, GMP-compliant ibogaine for large-scale clinical trials, a capability developed through its investment in PsyLabs.
Regulatory Hurdles and Competitive Landscape
Importantly, the executive order does not legalize ibogaine or any other psychedelic drug. A White House statement clarified that any rescheduling would be contingent on successful Phase 3 clinical trial results and subsequent FDA approval. FDA Commissioner Marty Makary indicated a decision on a related review could come "as soon as this summer."
The competitive landscape highlights Psyence's developmental stage. The company's lead drug candidate is NPX-5, a natural psilocybin capsule currently in Phase IIb trials in Australia for adjustment disorder in palliative cancer patients. This places it behind competitors like Compass Pathways, which has already submitted portions of its application for COMP360 following positive Phase 3 results. Compass CEO Kabir Nath welcomed the order, stating it could "quicken access without compromising rigorous science."
Industry experts caution that the policy shift does not lower the evidentiary bar for drug approval. "Nothing about any of this should lower the bar," stated Rob Barrow, CEO of Definium Therapeutics. This sentiment echoes recent regulatory actions, including the FDA's 2024 rejection of Lykos Therapeutics' MDMA-assisted therapy for PTSD.
Company Fundamentals and Risks
Psyence's corporate filings disclose considerable challenges common to early-stage biotechs: it has no approved products, generates no revenue, and has ongoing financing needs. The company also notes the risk of falling out of compliance with Nasdaq listing requirements, which could impact its stock liquidity and share price.
In response to the news, Psyence CEO Jody Aufrichtig cited "increasing global interest" in ibogaine and highlighted the company's "ethically grounded supply chain." The firm is positioning its supply-chain readiness as a strategic advantage as regulatory frameworks potentially evolve. However, the company itself acknowledges there is no guarantee the White House directive will materially impact its business or regulatory pathway.
The market's reaction underscores the high sensitivity of psychedelic-sector stocks to regulatory developments. While the order provides a framework for accelerated research and development, the path to commercialization for companies like Psyence remains long, costly, and fraught with scientific and regulatory uncertainty. Investors are clearly betting on a more favorable environment, but the ultimate test will be clinical success and FDA endorsement.